Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 8/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404850 | 0.92 | LMNA (0.38) | FASNCHRM2CHRM1CHRM3CCR5 | |
| SCHEMBL4412037 | 0.91 | LMNA (0.38) | LMNA | |
| SCHEMBL4405328 | 0.89 | TRPV6 (0.39) | CCR5LMNA | |
| SCHEMBL4396163 | 0.89 | CHRM2 (0.39) | FASNCHRM2CHRM1CHRM3CCR5 | |
| SCHEMBL6488116 | 0.88 | NR1H4 (0.36) | LMNA | |
| SCHEMBL4405694 | 0.88 | TP53 (0.36) | CHRM2CHRM1CHRM3LMNA | |
| SCHEMBL4398226 | 0.85 | MAPK7 (0.39) | CCR5LMNAMCHR1 | |
| SCHEMBL4403838 | 0.84 | LMNA (0.43) | LMNA | |
| SCHEMBL7148752 | 0.83 | CCR5 (0.36) | FASNCHRM2CHRM1CHRM3CCR5 | |
| SCHEMBL4402040 | 0.83 | LMNA (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | FASN 544/4885CHRM2 425/4885CHRM1 603/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | FASN 544/4885CHRM2 425/4885CHRM1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.